Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Nicola E AnnelsDavid MansfieldMehreen ArifCarmen Ballesteros-MerinoGuy R SimpsonMick DenyerSarbjinder S SandhuAlan A MelcherKevin J HarringtonBronwyn DaviesGough AuMark GroseIzhar BagwanBernard FoxRichard VileHugh MostafidDarren ShafrenHardev S PandhaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The acceptable safety profile of CAVATAK, proof of viral targeting, replication, and tumor cell death together with the virus-mediated increases in "immunological heat" within the tumor microenvironment all indicate that CAVATAK may be potentially considered as a novel therapeutic for NMIBC.